Highlight
Dual immune checkpoint blockade with ipilimumab and nivolumab failed to improve progression-free survival compared to standard temozolomide chemotherapy in MGMT-unmethylated newly diagnosed glioblastoma. The phase II trial did not meet its primary endpoint, resulting in early termination without proceeding to phase III. Safety profiles were consistent with known effects, and no new adverse signals emerged.
Molecular correlative studies and ongoing survival follow-up may inform future therapeutic strategies in this difficult-to-treat subgroup.
